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BACKGROUND
Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled 
glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treat-
ment for patients with chronic obstructive pulmonary disease (COPD) who have a high 
risk of exacerbations. The role of treatment with a LABA–LAMA regimen in these pa-
tients is unclear.
METHODS
We conducted a 52-week, randomized, double-blind, double-dummy, noninferiority 
trial. Patients who had COPD with a history of at least one exacerbation during the 
previous year were randomly assigned to receive, by inhalation, either the LABA inda-
caterol (110 μg) plus the LAMA glycopyrronium (50 μg) once daily or the LABA 
salmeterol (50 μg) plus the inhaled glucocorticoid fluticasone (500 μg) twice daily. 
The primary outcome was the annual rate of all COPD exacerbations.
RESULTS
A total of 1680 patients were assigned to the indacaterol–glycopyrronium group, and 
1682 to the salmeterol–fluticasone group. Indacaterol–glycopyrronium showed not only 
noninferiority but also superiority to salmeterol–fluticasone in reducing the annual rate 
of all COPD exacerbations; the rate was 11% lower in the indacaterol–glycopyrronium 
group than in the salmeterol–fluticasone group (3.59 vs. 4.03; rate ratio, 0.89; 95% 
confidence interval [CI], 0.83 to 0.96; P = 0.003). The indacaterol–glycopyrronium group 
had a longer time to the first exacerbation than did the salmeterol–fluticasone group 
(71 days [95% CI, 60 to 82] vs. 51 days [95% CI, 46 to 57]; hazard ratio, 0.84 [95% CI, 
0.78 to 0.91], representing a 16% lower risk; P<0.001). The annual rate of moderate or 
severe exacerbations was lower in the indacaterol–glycopyrronium group than in the 
salmeterol–fluticasone group (0.98 vs. 1.19; rate ratio, 0.83; 95% CI, 0.75 to 0.91; 
P<0.001), and the time to the first moderate or severe exacerbation was longer in the 
indacaterol–glycopyrronium group than in the salmeterol–fluticasone group (hazard 
ratio, 0.78; 95% CI, 0.70 to 0.86; P<0.001), as was the time to the first severe exacerbation 
(hazard ratio, 0.81; 95% CI, 0.66 to 1.00; P = 0.046). The effect of indacaterol–glycopyr-
ronium versus salmeterol–fluticasone on the rate of COPD exacerbations was indepen-
dent of the baseline blood eosinophil count. The incidence of adverse events and deaths 
was similar in the two groups. The incidence of pneumonia was 3.2% in the inda-
caterol–glycopyrronium group and 4.8% in the salmeterol–fluticasone group (P = 0.02).
CONCLUSIONS
Indacaterol–glycopyrronium was more effective than salmeterol–fluticasone in prevent-
ing COPD exacerbations in patients with a history of exacerbation during the previous 
year. (Funded by Novartis; FLAME ClinicalTrials.gov number, NCT01782326.)
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Exacerbations of chronic obstruc-tive pulmonary disease (COPD) are associ-ated with an accelerated decline in lung 
function,1-3 impaired quality of life,4 hospitaliza-
tion,5 and increased mortality.6 COPD exacerba-
tions are costly to health care systems.7 Thus, 
prevention of exacerbations is a key goal in the 
management of COPD.8
Inhaled long-acting bronchodilators not only 
control symptoms but also prevent COPD exacer-
bations.9-12 Inhaled glucocorticoids are also known 
to reduce the frequency of exacerbations and 
have been studied in combination with inhaled 
long-acting beta-agonists (LABAs).11,13,14 In one 
trial, the combination of a LABA plus an inhaled 
glucocorticoid (salmeterol–fluticasone) in fixed 
doses and the inhaled long-acting muscarinic 
antagonist (LAMA) tiotropium had similar effects 
on the rate of COPD exacerbations among pa-
tients with a history of exacerbation.15 Conse-
quently, treatment guidelines have recommended 
that either a LABA plus an inhaled glucocorti-
coid or a LAMA can be used to prevent COPD 
exacerbations in high-risk patients.8
Long-term use of glucocorticoids is associat-
ed with a small but important risk of pneumo-
nia16,17 and other adverse effects.18 An alternative 
to the combination of a LABA and an inhaled 
glucocorticoid for the prevention of COPD exac-
erbations in patients with a history of exacerba-
tion is a dual bronchodilator regimen of a LABA 
and a LAMA.19
In the FLAME trial, we investigated whether 
the LABA indacaterol (110 μg) plus the LAMA 
glycopyrronium (50 μg) once daily would be at 
least as effective as the LABA salmeterol (50 μg) 
plus the inhaled glucocorticoid fluticasone 
(500 μg) twice daily in preventing COPD exacer-
bations. Because recent studies have indicated 
that prevention of COPD exacerbations with in-
haled glucocorticoids may be related to the blood 
eosinophil count,20-22 the relationship between 
the baseline blood eosinophil count and the rate 
of exacerbations associated with each interven-
tion was examined prospectively.
Me thods
Trial Design and Oversight
The FLAME trial was a multicenter, randomized, 
double-blind, double-dummy, parallel-group, non-
inferiority trial (see Fig. S1 in the Supplementary 
Appendix, available with the full text of this 
article at NEJM.org). From July 2013 through 
September 2015, patients were enrolled at 356 
centers in 43 countries. A 1-week screening 
period was followed by a 4-week run-in period, 
during which all patients were treated with in-
haled tiotropium at a dose of 18 μg once daily. 
After the run-in period, tiotropium was discon-
tinued, and the patients were randomly assigned, 
in a 1:1 ratio, to receive either indacaterol (110 μg) 
plus glycopyrronium (50 μg) once daily or sal-
meterol (50 μg) plus fluticasone (500 μg) twice 
daily for 52 weeks; patients were followed for an 
additional 30 days after discontinuation of the 
study regimen. Open-label salbutamol (100 μg) 
was provided as rescue medication. Additional 
details are provided in Section 3 in the Supple-
mentary Appendix.
The sponsor (Novartis) developed the proto-
col, with guidance from the first author and ad-
vice from the other academic authors. The first 
draft of the manuscript was written by the first 
and second authors. Editorial and technical 
support in the preparation of the manuscript 
was provided by a professional medical writer at 
CircleScience (an Ashfield company, part of UDG 
Healthcare); the medical writing support was 
funded by Novartis. All the authors reviewed and 
edited the manuscript and made the decision to 
submit the manuscript for publication. All the 
authors contributed to the interpretation of the 
data and had access to the full data (nondisclo-
sure agreements were in place). The trial was 
approved by the ethics committee at each trial 
center, and all the patients provided written in-
formed consent. All the authors vouch for the 
accuracy and completeness of the data and for 
the fidelity of the trial to the protocol (available 
at NEJM.org). Statistical analyses were performed 
by a statistician at DataMap. Novartis funded the 
trial and its analyses, performed trial monitoring 
and reporting, provided oversight, verified key 
results provided by DataMap, and had no other 
role in the trial.
Patients
We enrolled patients 40 years of age or older 
who had COPD with a grade of 2 or higher on 
the modified Medical Research Council scale 
(which ranges from 0 to 4, with higher grades 
indicating more severe dyspnea; a minimum 
clinically important difference has not been de-
termined23), a post-bronchodilator forced expira-
tory volume in 1 second (FEV1) of at least 25% to 
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less than 60% of the predicted value, and a post-
bronchodilator ratio of FEV1 to forced vital capac-
ity (FVC) of less than 0.70. Patients were required 
to have a documented history of at least one 
COPD exacerbation during the previous year for 
which they received treatment with systemic 
glucocorticoids, antibiotic agents, or both. Addi-
tional details are provided in Section 2 and Table 
S1 in the Supplementary Appendix.
Outcome Measures
The primary objective of this trial was to show 
whether indacaterol–glycopyrronium would be 
noninferior to salmeterol–fluticasone in reducing 
the rate of COPD exacerbations. The primary 
outcome was the annual rate of all COPD exac-
erbations (mild, moderate, or severe). An impor-
tant secondary objective, if noninferiority could 
be established, was to show whether indacaterol–
glycopyrronium would be superior to salmeterol–
fluticasone in reducing the annual rate of all 
COPD exacerbations.
The protocol includes a list of 27 secondary 
outcome measures; we report data for 19 of these 
outcomes here and in Sections 4 and 5 in the 
Supplementary Appendix. The outcomes for which 
data are not reported herein can be found at 
ClinicalTrials.gov (https:/ / clinicaltrials . gov/ ct2/ 
 show/ results/ NCT01782326). Secondary outcomes 
included the times to the first COPD exacerba-
tion of any severity, the first moderate or severe 
COPD exacerbation, and the first severe COPD 
exacerbation and the annual rates of moderate 
or severe exacerbations and of severe exacerba-
tions. We also assessed trough FEV1, the stan-
dardized area under the curve for FEV1 from 0 to 
12 hours (in a subgroup of patients), health 
status (measured by the total score on the St. 
George’s Respiratory Questionnaire for COPD 
[SGRQ-C], on which scores range from 0 to 100, 
with higher scores indicating worse health sta-
tus, and the minimum clinically important dif-
ference is 4 points, as compared with the score 
with placebo24), and the use of rescue medication.
COPD exacerbations, which were defined ac-
cording to the criteria of Anthonisen et al.,25 
were categorized as mild (involving worsening 
of symptoms for >2 consecutive days but not 
leading to treatment with systemic glucocorti-
coids or antibiotics), moderate (leading to treat-
ment with systemic glucocorticoids, antibiotics, 
or both), or severe (leading to hospital admis-
sion or a visit to the emergency department that 
lasted >24 hours in addition to treatment with 
systemic glucocorticoids, antibiotics, or both). 
Patients recorded daily symptoms and the use of 
rescue medication in an electronic diary (Fig. S2 
in the Supplementary Appendix). When worsen-
ing of symptoms met the prespecified criteria 
for exacerbation, alerts were triggered in the 
electronic diary, and patients were advised to 
contact their trial site.
The safety of indacaterol–glycopyrronium and 
salmeterol–fluticasone was also assessed. An 
independent adjudication committee assessed 
blinded safety data. Radiographic imaging was 
required to confirm the presence of pneumonia. 
Additional details are provided in Section 3 in 
the Supplementary Appendix.
Statistical Analysis
The noninferiority margin of 15% (correspond-
ing to a rate ratio for exacerbations with inda-
caterol–glycopyrronium versus salmeterol–fluti-
casone of 1.15) was based on a previous study,11 
in which the rate ratio for moderate or severe 
exacerbations with salmeterol–fluticasone versus 
placebo was 0.75. If the FLAME trial could rule 
out a 15% higher rate of exacerbations with in-
dacaterol–glycopyrronium than with salmeterol–
fluticasone, the rate ratio for exacerbations with 
indacaterol–glycopyrronium versus placebo would 
be 0.8625, thus leading to a meaningfully lower 
rate of exacerbations with indacaterol–glycopyr-
ronium than with placebo of more than 13.75%.
We calculated that a sample of approximately 
3332 patients would be required to give the trial 
more than 95% power to rule out a 15% higher 
rate of COPD exacerbations of any severity with 
indacaterol–glycopyrronium than with salmeterol–
fluticasone, at a one-sided error rate of 0.025, 
assuming a rate of dropouts or major protocol 
deviations of 30%. The modified intention-to-
treat population included all patients who under-
went randomization, received at least one dose 
of a drug during the treatment period, and did 
not have major violations of compliance with 
Good Clinical Practice guidelines before un-
blinding occurred. The per-protocol population 
included all patients in the modified intention-
to-treat population who did not have any major 
protocol deviations (definitions of major proto-
col deviations were specified before unblinding 
occurred). The main analysis of the primary 
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outcome was performed in the per-protocol 
population; a supportive analysis of that out-
come was performed in the modified intention-
to-treat population. Analyses of all other efficacy 
outcomes were performed in the modified inten-
tion-to-treat population. All efficacy analyses, 
unless stated otherwise, were based on on-
treatment data (i.e., for participants who discon-
tinued treatment early, only the data obtained 
while they were receiving treatment were used).
The number of exacerbations that occurred 
during the treatment period was analyzed with 
the use of a negative binomial model that in-
cluded terms for treatment, baseline smoking 
status, use of inhaled glucocorticoids at the time 
of screening, severity of airflow limitation, and 
geographic region as fixed effects and baseline 
total symptom score (on a scale ranging from 
0 to 18, with higher total scores indicating worse 
symptoms) and 1-year history of COPD exacerba-
tions as covariates. The overall two-sided type I 
error rate for the noninferiority and subsequent 
superiority analyses was controlled at 0.05. Non-
inferiority of indacaterol–glycopyrronium to sal-
meterol–fluticasone in reducing the annual rate 
of COPD exacerbations could be claimed if the 
upper limit of the 95% confidence interval of the 
rate ratio for exacerbations with indacaterol–gly-
copyrronium versus salmeterol–fluticasone was 
less than 1.15; if noninferiority was established, 
superiority of indacaterol–glycopyrronium to 
salmeterol–fluticasone in reducing the annual 
rate of COPD exacerbations could be claimed if 
the upper limit of the same 95% confidence in-
terval was less than 1.
Although the per-protocol analysis was pre-
specified as the main analysis of the primary 
outcome and the modified intention-to-treat 
analysis as the supportive analysis, it was impor-
tant to achieve consistent results in the two 
analyses in order to draw convincing conclu-
sions regarding noninferiority and superiority.26,27 
No adjustments for multiple testing were per-
formed for the other outcomes.
Rates of exacerbations were also analyzed in 
19 prespecified subgroup analyses, defined ac-
cording to 15 baseline characteristics, including 
baseline blood eosinophil count, to assess the 
consistency of the treatment effect. All exacerba-
tion outcomes were analyzed with the use of the 
negative binomial model. The outcomes for the 
time to the first event were analyzed with the use 
of a Cox regression model, which included the 
same terms as the negative binomial model. Ad-
ditional details are provided in Section 3 in the 
Supplementary Appendix.
R esult s
Patients
During the run-in period, 3.6% of the patients 
discontinued treatment because of an exacerba-
tion. A total of 3362 patients underwent ran-
domization; 1680 were assigned to the inda-
caterol–glycopyrronium group, and 1682 to the 
salmeterol–fluticasone group. Of the 3362 pa-
tients, 4 were excluded from all analyses because 
they did not receive any trial drugs (additional 
details are provided in Section 4 in the Supple-
mentary Appendix). The per-protocol population 
included 3084 patients, and the modified inten-
tion-to-treat population included 3354 (Fig. 1). 
The rates of treatment discontinuation were 
16.6% in the indacaterol–glycopyrronium group 
and 19.0% in the salmeterol–fluticasone group 
(Fig. 1, and Fig. S4 in the Supplementary Ap-
pendix). The reasons for discontinuation during 
the screening, run-in, and treatment periods are 
shown in Figure 1, and in Figure S3 in the 
Supplementary Appendix.
The demographic characteristics and disease 
history were well balanced between the two 
treatment groups (Table 1). A total of 19.3% of 
the patients had a history of two or more moder-
ate or severe exacerbations during the previous 
year, and 56.3% were using inhaled glucocorti-
coids at the time of screening. The rate of adher-
ence to the treatment regimens was higher than 
99%. Additional details are provided in Tables 
S2 and S3 and Section 4 in the Supplementary 
Appendix.
Primary Outcome
In the per-protocol population, the annual rate 
of all COPD exacerbations was 3.59 (95% confi-
dence interval [CI], 3.28 to 3.94) in the inda-
caterol–glycopyrronium group and 4.03 (95% CI, 
3.68 to 4.41) in the salmeterol–fluticasone group 
(rate ratio, 0.89 [95% CI, 0.83 to 0.96], repre-
senting an 11% lower rate; P = 0.003) (Fig. 2A, 
and Fig. S5A in the Supplementary Appendix). 
The upper limit of the 95% confidence interval for 
the rate ratio was less than the noninferiority 
margin of 1.15, and therefore, indacaterol–gly-
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copyrronium showed noninferiority to salme-
terol–fluticasone with regard to the annual rate 
of all COPD exacerbations. Noninferiority was 
also established in the modified intention-to-
treat population (rate of all COPD exacerbations, 
3.59 [95% CI, 3.29 to 3.92] in the indacaterol–
glycopyrronium group vs. 4.09 [95% CI, 3.75 to 
4.46] in the salmeterol–fluticasone group; rate 
ratio, 0.88; 95% CI, 0.82 to 0.94; P<0.001) (Fig. 
2A). Similar results were observed in additional 
sensitivity analyses performed with the addition 
of data on exacerbations and follow-up time 
from patients who discontinued treatment early 
(further details are provided in Table S4 and Sec-
tion 4 in the Supplementary Appendix).
In a secondary analysis of the primary out-
come that was adjusted for multiple testing, in-
dacaterol–glycopyrronium showed superiority to 
salmeterol–fluticasone in reducing the annual 
rate of all COPD exacerbations. In both the per-
protocol and modified intention-to-treat popula-
tions, the upper limits of the same 95% confi-
dence intervals for the rate ratio were less than 1 
(Fig. 2A).
Characteristic
Indacaterol– 
Glycopyrronium Group  
(N = 1680)
Salmeterol– 
Fluticasone Group  
(N = 1682)
All Patients 
(N = 3362)
Age — yr 64.6±7.9 64.5±7.7 64.6±7.8
Male sex — no. (%) 1299 (77.3) 1258 (74.8) 2557 (76.1)
Duration of COPD — yr 7.2±5.3 7.3±5.5 7.3±5.4
Use of inhaled glucocorticoids at screening — no. (%) 954 (56.8) 939 (55.8) 1893 (56.3)
Current smoker — no. (%) 664 (39.5) 669 (39.8) 1333 (39.6)
Severity of COPD — no. (%)†
Group A 2 (0.1) 0 2 (0.1)
Group B 400 (23.8) 422 (25.1) 822 (24.4)
Group C 1 (0.1) 2 (0.1) 3 (0.1)
Group D 1265 (75.3) 1249 (74.3) 2514 (74.8)
Post-bronchodilator FEV1 — liters 1.2±0.3 1.2±0.4 1.2±0.3
Post-bronchodilator FEV1 — % of predicted value 44.0±9.5 44.1±9.4 44.1±9.5
Post-bronchodilator ratio of FEV1 to FVC — % 41.7±9.8 41.5±9.9 41.6±9.9
Total score on the SGRQ-C‡ 47.3±15.8 47.2±15.9 47.3±15.8
*  Plus–minus values are means ±SD. There were no significant differences between treatment groups, on the basis of 
Student’s t-tests for continuous variables and chi-square tests (or Fisher’s exact tests, as appropriate) for categorical 
variables. COPD denotes chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 second, and FVC 
forced vital capacity.
†  The severity of COPD was determined on the basis of the 2015 Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) staging system, in which group A indicates low risk and low symptom burden, group B low risk and high 
symptom burden, group C high risk and low symptom burden, and group D high risk and high symptom burden.
‡  Scores on the St. George’s Respiratory Questionnaire for COPD (SGRQ-C) range from 0 to 100, with higher scores in-
dicating worse health status; the minimum clinically important difference is 4 points, as compared with the score with 
placebo.24
Table 1. Baseline Characteristics of the Patients.*
Figure 1 (facing page). Screening, Randomization, 
Treatment, and Analysis.
Of the patients who entered the run-in period, 179 
(3.6%) discontinued because of an exacerbation; this 
number is derived from the case report forms for ex-
acerbation and inclusion and exclusion, because there 
was no option for exacerbation as a reason for discontin-
uation on the case report forms. Patients were included 
in the safety analysis for the treatment they received; 
one patient who had been assigned to the salmeterol–
fluticasone group had mistakenly received indacaterol–
glycopyrronium before discontinuing treatment. Patients 
who discontinued during the treatment period because 
of technical problems were from one site that was closed 
prematurely. Patients who were excluded from the per-
protocol analysis may be counted for more than one 
reason for exclusion.
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Figure 2. Trial Outcomes.
Panel A shows the rate ratio for all exacerbations (mild, moderate, and severe) in the indacaterol–glycopyrronium 
group versus the salmeterol–fluticasone group. The bars indicate 95% confidence intervals. The modified intention-
to-treat population included all patients who underwent randomization, received at least one dose of a trial drug 
during the treatment period, and did not have major violations of compliance with Good Clinical Practice guidelines 
before unblinding occurred. The per-protocol population included all patients in the modified intention-to-treat 
population who did not have any major protocol deviations (definitions of major protocol deviations were specified 
before unblinding occurred). Panel B shows the time to the first exacerbation of any severity, the time to the first 
moderate or severe exacerbation, and the time to the first severe exacerbation in the indacaterol–glycopyrronium 
group and the salmeterol–fluticasone group. The analyses were performed in the modified intention-to-treat popu-
lation. Patients at risk are patients who were still receiving treatment and had not had an event.
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Secondary Outcomes
Analyses of all other efficacy outcomes were 
performed in the modified intention-to-treat 
population. The indacaterol–glycopyrronium 
group had a longer time to first exacerbation 
than did the salmeterol–fluticasone group (me-
dian, 71 days [95% CI, 60 to 82] vs. 51 days 
[95% CI, 46 to 57]; hazard ratio, 0.84 [95% CI, 
0.78 to 0.91], representing a 16% lower risk; 
P<0.001) (Fig. 2B). The annual rate of moderate 
or severe COPD exacerbations (i.e., exacerbations 
that required the use of health care services) was 
17% lower in the indacaterol–glycopyrronium 
group than in the salmeterol–fluticasone group 
(0.98 [95% CI, 0.88 to 1.10] vs. 1.19 [95% CI, 
1.07 to 1.32]; rate ratio, 0.83; 95% CI, 0.75 to 
0.91; P<0.001) (Fig. S5B in the Supplementary 
Appendix). The indacaterol–glycopyrronium group 
had a longer time to the first moderate or severe 
exacerbation than did the salmeterol–fluticasone 
group (127 days [95% CI, 107 to 149] vs. 87 days 
[95% CI, 81 to 103]; hazard ratio, 0.78 [95% CI, 
0.70 to 0.86], representing a 22% lower risk; 
P<0.001) (Fig. 2B); because less than 50% of 
patients in the indacaterol–glycopyrronium group 
had an exacerbation, the time by which at least 
25% of patients had a first moderate or severe 
exacerbation was calculated instead of the me-
dian time. In addition, the indacaterol–glycopyr-
ronium group had a significantly longer time to 
the first severe exacerbation than did the salme-
terol–fluticasone group, with a 19% lower risk 
(hazard ratio, 0.81; 95% CI, 0.66 to 1.00; 
P = 0.046) (Fig. 2B). The annual rate of severe 
COPD exacerbations was 0.15 (95% CI, 0.11 to 
0.19) in the indacaterol–glycopyrronium group 
and 0.17 (95% CI, 0.13 to 0.22) in the salmeterol–
fluticasone group (rate ratio, 0.87; 95% CI, 0.69 
to 1.09; P = 0.23). The number of exacerbation 
events according to severity is provided in Table 
S5 in the Supplementary Appendix.
The annual rate of moderate or severe COPD 
exacerbations was analyzed according to base-
line blood eosinophil count (<2% vs. ≥2%). Among 
patients with baseline blood eosinophil counts 
lower than 2%, the rate was significantly lower 
in the indacaterol–glycopyrronium group than 
in the salmeterol–fluticasone group (0.99 [95% 
CI, 0.86 to 1.14] vs. 1.24 [95% CI, 1.09 to 1.43]; 
rate ratio, 0.80; 95% CI, 0.68 to 0.93; P = 0.004); 
among patients with baseline blood eosinophil 
counts of 2% or higher, the rate was also sig-
nificantly lower in the indacaterol–glycopyrro-
nium group than in the salmeterol–fluticasone 
group (0.98 [95% CI, 0.87 to 1.11] vs. 1.15 [95% 
CI, 1.02 to 1.30]; rate ratio, 0.85; 95% CI, 0.75 to 
0.96; P = 0.01). Three other analyses in sub-
groups defined according to different cutoffs of 
baseline blood eosinophil counts provided simi-
lar results (data not shown). No meaningful in-
teraction was seen between the rate of all COPD 
exacerbations or moderate or severe COPD exac-
erbations and previous therapy or other baseline 
characteristics (Fig. 3, and Fig. S6A and S6B in 
the Supplementary Appendix). Additional details 
are provided in Section 4 in the Supplementary 
Appendix.
The change from baseline in trough FEV1 was 
significantly greater in the indacaterol–glycopyr-
ronium group than in the salmeterol–fluticasone 
group, with a between-group difference of 62 ml 
at week 52 (P<0.001). The standardized area 
under the curve for FEV1 from 0 to 12 hours was 
measured in a subgroup of 556 patients; the 
change from baseline was significantly greater 
in the indacaterol–glycopyrronium group than in 
the salmeterol–fluticasone group, with a between-
group difference of 110 ml at week 52 (P<0.001). 
The improvement (decrease in score) over time 
in the total score on the SGRQ-C was greater in 
the indacaterol–glycopyrronium group than in the 
salmeterol–fluticasone group, with differences 
between the indacaterol–glycopyrronium group 
and the salmeterol–fluticasone group ranging 
from −1.2 points at week 12 to −1.8 points at 
week 52 (P<0.01 for both comparisons). At week 
52, the percentage of patients who had a clini-
cally important decrease of at least 4 points in 
the total score on the SGRQ-C was significantly 
higher in the indacaterol–glycopyrronium group 
than in the salmeterol–fluticasone group (49.2% 
vs. 43.7%; odds ratio, 1.30; P<0.001). The de-
crease over time in the use of rescue medication 
was also greater in the indacaterol–glycopyrro-
nium group than in the salmeterol–fluticasone 
group. (For additional details on these second-
ary outcomes, see Fig. S7, Tables S6 and S7, and 
Section 4 in the Supplementary Appendix.)
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Safety
The incidence of adverse events, including seri-
ous adverse events, was similar in the two treat-
ment groups (Table 2). A total of 24 participants 
in each group (1.4%) died; the most common 
causes of death were respiratory and cardiovas-
cular causes (Tables S8 and S9 in the Supple-
mentary Appendix). The incidence of pneumonia 
was 3.2% in the indacaterol–glycopyrronium 
group and 4.8% in the salmeterol–fluticasone 
Figure 3. Subgroup Analysis of the Rate of All Exacerbations.
The analysis was performed in the modified intention-to-treat population. Race was self-reported. The severity of airflow limitation was 
determined on the basis of the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system, in which moderate 
disease is indicated by a forced expiratory volume in 1 second (FEV1) of 50 to 79% of the predicted value, severe disease by an FEV1 of 
30 to 49% of the predicted value, and very severe disease by an FEV1 of less than 30% of the predicted value. The severity of chronic ob-
structive pulmonary disease (COPD) was determined on the basis of the 2015 GOLD staging system, in which group A indicates low risk 
and low symptom burden, group B low risk and high symptom burden, group C high risk and low symptom burden, and group D high 
risk and high symptom burden. COPD denotes chronic obstructive pulmonary disease, LABA long-acting beta-agonist, and LAMA long-
acting muscarinic antagonist.
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group (P = 0.02). In a subgroup of 535 patients, 
the median percentage change over a period of 
52 weeks in the ratio of 24-hour urinary cortisol 
to creatinine was 5.62% in the indacaterol–gly-
copyrronium group and –10.39% in the salme-
terol–fluticasone group (Fig. S8 in the Supple-
mentary Appendix).
Discussion
This clinical trial was powered for a noninferi-
ority analysis to determine whether the combi-
nation of a LABA (indacaterol) and a LAMA 
(glycopyrronium) would be as effective as the 
combination of a LABA (salmeterol) and an in-
haled glucocorticoid (fluticasone) for the preven-
tion of COPD exacerbations. The LABA–LAMA 
regimen showed not only noninferiority but also, 
on a subsequent superiority analysis, consistent 
superiority to the LABA–inhaled glucocorticoid 
regimen for all outcomes related to exacerbations, 
lung function, and health status.
Clinical guidelines and strategy documents 
for COPD8,28 have recommended that, in patients 
at risk for exacerbations, first-line therapy should 
be either a LABA plus an inhaled glucocorticoid or 
a LAMA. One previous trial showed no difference 
between the use of a LABA–inhaled glucocorti-
coid regimen and the use of LAMA monotherapy 
with regard to exacerbation rates.15 However, a 
recent study showed that combined bronchodila-
tor therapy with a LABA and a LAMA had greater 
efficacy in the reduction of exacerbation rates 
than did LAMA monotherapy.19 Among patients 
Variable
Indacaterol– 
Glycopyrronium Group 
(N = 1678)
Salmeterol– 
Fluticasone Group 
(N = 1680)
number (percent)
Patients with ≥1 adverse event 1459 (86.9) 1498 (89.2)
Adverse events that occurred in ≥3% of either treatment group†
Worsening of chronic obstructive pulmonary disease 1299 (77.4) 1374 (81.8)
Nasopharyngitis 197 (11.7) 195 (11.6)
Viral upper respiratory tract infection 132 (7.9) 138 (8.2)
Bacterial upper respiratory tract infection 125 (7.4) 168 (10.0)
Lower respiratory tract infection 82 (4.9) 98 (5.8)
Upper respiratory tract infection‡ 81 (4.8) 83 (4.9)
Pneumonia 53 (3.2) 80 (4.8)
Cough 50 (3.0) 51 (3.0)
Dyspnea 49 (2.9) 51 (3.0)
Influenza 35 (2.1) 56 (3.3)
Oral candidiasis 20 (1.2) 71 (4.2)
Serious adverse event§ 308 (18.4) 334 (19.9)
Death 24 (1.4) 24 (1.4)
Patients who discontinued because of adverse event 126 (7.5) 143 (8.5)
Patients who discontinued because of serious adverse event 85 (5.1) 87 (5.2)
Patients who discontinued because of nonserious adverse event 49 (2.9) 70 (4.2)
*  The safety analysis included patients who received a drug during the treatment period. Patients were included in the 
analysis for the treatment they received; one patient who had been assigned to the salmeterol–fluticasone group had 
mistakenly received indacaterol–glycopyrronium.
†  These events were coded according to preferred terms in the Medical Dictionary for Regulatory Activities, a standardized 
dictionary for clinical trials.
‡  This category includes upper respiratory tract infections not otherwise specified as viral or bacterial.
§  A definition of serious adverse events is provided in Section 3 in the Supplementary Appendix.
Table 2. Adverse Events and Serious Adverse Events.*
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who had been receiving combined treatment with 
a LABA, an inhaled glucocorticoid, and a LAMA, 
withdrawal from the inhaled glucocorticoid did 
not increase the exacerbation rate significantly,29 
a finding that further supports the hypothesis 
that inhaled glucocorticoids may not be essential 
for the prevention of COPD exacerbations in pa-
tients receiving therapy with a LABA and a LAMA.
The LABA–LAMA regimen had superior and 
consistent effects with regard to COPD exacerba-
tions of all severities, including exacerbations 
requiring the use of health care services. Exacer-
bations were carefully monitored with daily 
symptom recordings in electronic diaries,4 which 
allowed us to document all exacerbations, includ-
ing those requiring the use of health care ser-
vices. Studies have shown underreporting of ex-
acerbation events (mild exacerbations), yet these 
unreported events have an effect on patients’ 
health status.30-32 Therefore, in this trial, exacer-
bations of all severities were assessed for the 
primary outcome to reflect the importance of 
preventing every exacerbation. Capturing all exac-
erbations is a major strength of this trial, and 
we have found a very consistent benefit of dual 
bronchodilation therapy in reducing exacerba-
tions of all severities.
Post hoc analyses of data from trials of LABA–
inhaled glucocorticoid regimens for COPD have 
suggested that these regimens are more benefi-
cial in reducing the rate of exacerbations among 
patients with elevated blood eosinophil counts 
(e.g., ≥2%) than among patients with lower 
eosinophil counts.20-22 This suggests that a higher 
eosinophil count may be associated with a greater 
response to inhaled glucocorticoids. Therefore, 
the FLAME trial prospectively examined the re-
lationship between blood eosinophil counts and 
exacerbation outcomes. In both the subgroup of 
patients with blood eosinophil counts lower than 
2% and the subgroup of patients with counts of 
2% or higher, the rates of moderate or severe 
exacerbations and of all exacerbations were sig-
nificantly lower in the indacaterol–glycopyrro-
nium group than in the salmeterol–fluticasone 
group, a finding that suggests that the LABA–
LAMA regimen is more effective in reducing the 
rate of exacerbations than the LABA–inhaled 
glucocorticoid regimen in both eosinophil sub-
groups.
The superiority of indacaterol–glycopyrronium 
with respect to lung function was expected, since 
a combination of two bronchodilators improves 
lung function to a greater degree than does a 
combination of a LABA and an inhaled gluco-
corticoid.33-35 Further evidence of a benefit with 
respect to symptoms was seen with the greater 
decrease in the use of rescue medication and the 
greater improvement in health status (decrease in 
SGRQ-C score) in the indacaterol–glycopyrronium 
group than in the salmeterol–fluticasone group.
A potential limitation of the study is that some 
patients who were treated with a LABA–inhaled 
glucocorticoid regimen before enrollment and 
were then assigned to the indacaterol–glycopyr-
ronium group may have had withdrawal effects 
from the long-term use of their previous regi-
men, which could have resulted in an increase in 
exacerbations. There was no evidence that pa-
tients who had been receiving inhaled glucocor-
ticoids before the trial withdrew from the trial 
during the run-in period at higher rates than did 
patients who had not been receiving inhaled 
glucocorticoids, and exacerbation rates during 
the run-in period were low. In addition, analyses 
of exacerbation rates according to previous ther-
apy showed no meaningful interaction between 
the treatment and the type of maintenance 
therapy the patient had previously received.
It may also be argued that our trial design 
favored LABA–LAMA therapy over LABA–inhaled 
glucocorticoid therapy because the LABA–LAMA 
regimen was administered once daily, whereas 
the LABA–inhaled glucocorticoid regimen was 
administered twice daily. However, there is evi-
dence that once-daily administration of a LABA–
inhaled glucocorticoid regimen is no more effec-
tive than twice-daily administration with respect 
to lung function.36 The once-daily dose of inda-
caterol–glycopyrronium is approved worldwide, 
except in the United States, where a lower, twice-
daily dose of indacaterol–glycopyrronium is ap-
proved. Trials have shown that the twice-daily 
regimen has effects on lung function that are 
similar to those observed with a once-daily dos-
ing regimen, but no direct comparison has been 
performed.37,38
Our trial used electronic diaries to flag exac-
erbations, and thus higher rates of all exacerba-
tions were reported in this trial than in most 
trials assessing exacerbations, although this dif-
ference is unlikely to bias treatment compari-
sons. Because mild exacerbations were the most 
common events seen in this trial, it is possible 
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that inclusion of such events could have made it 
more likely for us to conclude noninferiority, as-
suming a lack of difference between treatments 
with respect to the mild exacerbations; however, 
the fact that the rates of mild exacerbations and 
of moderate and severe exacerbations combined 
were lower in the indacaterol–glycopyrronium 
group than in the salmeterol–fluticasone group 
is reassuring.
The consistent exacerbation outcomes have 
major implications for COPD management, espe-
cially among patients with a history of exacerba-
tion. Confirmation of these findings with the 
use of other combinations of long-acting bron-
chodilators would provide additional evidence to 
support the first-line use of a LABA–LAMA regi-
men in this patient population. However, we 
cannot exclude the possibility that some patients 
may benefit from the addition of inhaled gluco-
corticoids.
In conclusion, we found that among patients 
with COPD who had a history of exacerbation 
during the previous year, indacaterol–glycopyr-
ronium was consistently more effective than 
salmeterol–fluticasone in preventing exacerba-
tions and was associated with no detectable in-
crease in adverse events.
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